Deferred consent in emergency situations exceptionally permits the first trial intervention to begin before consent and before full information is provided. It is intended solely for the narrow emergency scenario defined in Article 35 of Regulation (EU) No 536/2014. Consent is then obtained without delay for continuation of trial participation; it is not a general retrospective approval for research.
Requirements and Scope of Application
The decision to include the subject must be made at the time of the first intervention according to the protocol. Due to a sudden life-threatening or other sudden serious condition, the subject cannot provide prior consent or be informed. Within the therapeutic window, the legally designated representative must also be unable to be fully informed and provide consent in time. The investigator further confirms that no previously expressed objection by the subject is known.
The provision further requires scientific grounds for a possible direct clinically relevant benefit to the subject, such as measurable improvement in health, alleviation of suffering, or diagnosis. The trial must be directly related to the condition preventing prior consent and must by its nature be feasible only in emergency situations. It may cause only minimal risk and minimal burden compared to standard treatment.
Conduct and Documentation
Following the intervention, the investigator obtains consent without undue delay and provides the information as soon as possible. For subjects lacking capacity to consent and minors, the investigator initially approaches the legally designated representative; for other subjects, the investigator approaches either the subject or the representative, whichever can be reached first. If capacity to consent is subsequently acquired, the subject’s own consent must be obtained for continued participation.
The involvement of ethics, medical management, and data protection in the preparation does not serve to delay, but to ensure capacity to act in an emergency. Complete documentation must also include negative findings, such as that no previously expressed objection was known and why the representative was not reachable or not capable of decision-making within the therapeutic window.
Distinction
Regular consent is based on prior comprehensible information, opportunity for questions, and voluntary decision before participation. Deferred consent is a narrowly limited exception because the emergency situation makes precisely this sequence impossible. Time pressure in the project, staff shortages, or late approach are expressly insufficient.
Consent of the legal representative must also be obtained in principle before participation. Article 35 applies only when this is not possible within the therapeutic window. The representative is therefore not bypassed, but involved without delay as soon as this is possible; their action does not subsequently replace the consent of the subject once the subject is capable of consenting.
The exception must be precisely prepared in the protocol and in the information documents. This includes the description of the emergency situation, the medically justified therapeutic window, the criteria for direct benefit, and the process for determining any prior objection. The site must clearly define who documents the inclusion decision, who contacts the representative, and how subsequent information is tracked. Any delay that is not medically justified may call into question the justification for the exception. Likewise, subsequent consent must not be treated as a mere formality: it determines continued participation and must convey all information according to Article 29. Refusal or withdrawal must be respected and implemented in practice. Precise documentation subsequently permits verification that the emergency provision was applied individually and not replaced by organizational routines.
All steps require a clear timestamp. It shows the sequence of initial intervention, inclusion decision, contact attempts, information, and subsequent consent. This temporal transparency is essential because the justification for the exception depends precisely on the emergency situation and the therapeutic window.
The related concepts of informed consent, consent of minors, and vulnerable populations remain fully applicable. Deferred consent changes only the temporal sequence of information and consent in the narrow emergency situation, not the protective rights of the subject.
Relevance for clinical trials
The emergency provision requires particularly careful preparation: inclusion criteria, therapeutic window, objection inquiry, sequence of contact attempts, and subsequent information must be unambiguous in the protocol and in site processes. The exception must not be devalued by a routine shortcut. Monitoring must verify that each inclusion individually and temporally documents the legal requirements.
Full-service CROs such as Mediconomics support the design of emergency-specific protocol sections, consent documents, and training of trial sites. They coordinate monitoring, documentation reviews, medical queries, and follow-up of subsequent consent for continuation of trial participation.
Frequently Asked Questions (FAQ)
Is time pressure alone a reason for deferred consent?
No. All requirements of Article 35 must be met, in particular the acute medical emergency and the lack of possibility within the therapeutic window.
Must a benefit to the subject be possible?
Yes. There must be scientific grounds for a possible direct clinically relevant benefit to the subject.
What happens if the subject subsequently acquires capacity to consent?
For continued participation, the subject’s own consent must be obtained as soon as possible.
Regulatory References
- Regulation (EU) No 536/2014, Article 35 — defines the requirements for trials in emergency situations.
- Regulation (EU) No 536/2014, Article 29 — regulates the general requirements for consent.
- European Commission Q on Regulation (EU) No 536/2014 — explains the application of the emergency provision.
